**All Interactions with Zalcitabine (Hivid)**

| **Coadministered Drug** | **Dose of Drug** | **Dose of Zalcitabine** | **Effect on Drug Levels** | **Effect on Zalcitabine Levels** | **Potential Clinical Effects** | **Mechanism of Interaction** | **Management** |
| --- | --- | --- | --- | --- | --- | --- | --- |
| Antacids[85](http://arv.ucsf.edu/insite?page=ar-00-02&param=22&post=4#85)  (Maalox, Mylanta, Riopan, Milk of Magnesia, others) | 30 ml x 1 | 1.5 mg x 1 | Not studied | Zalcitabine AUC: decreased 25% | Decreased zalcitabine absorption | - | Administer zalcitabine 1 hour before or 2 hours after antacid |
| Cimetidine[85](http://arv.ucsf.edu/insite?page=ar-00-02&param=22&post=4#85)  (Tagamet)(Tagamet) | - | - | Not studied | Not studied | Increased zalcitabine effects | Inhibition of renal tubular secretion by cimetidine | Consider alternative agents  *Alternative Agents*:  **Famotidine Nizatidine Ranitidine** |
| Foscarnet[232](http://arv.ucsf.edu/insite?page=ar-00-02&param=22&post=4#232),[85](http://arv.ucsf.edu/insite?page=ar-00-02&param=22&post=4#85)  (Foscavir) | - | - | No significant change | No significant change | - | - | No dose adjustment necessary |
| Loperamide[85](http://arv.ucsf.edu/insite?page=ar-00-02&param=22&post=4#85)  (Imodium, Imodium A-D)(Imodium) | 4 mg 16 hours before zalcitabine, 2 mg at 10 hours and 4 hours before zalcitabine, and 2 mg 2 hours after zalcitabine dose | 1.5 mg x 1 dose | Not reported | Not reported | - | - | No dose adjustment necessary |
| Metoclopramide[85](http://arv.ucsf.edu/insite?page=ar-00-02&param=22&post=4#85)  (Reglan)(Reglan) | 10 mg 1 hour before, 10 mg 4 hours after zalcitabine dose | 1.5 mg x 1 dose | Not studied | Zalcitabine AUC: decreased 16-21% | - | - | No dose adjustment necessary |
| **Coadministered Drug** | **Dose of Drug** | **Dose of Zalcitabine** | **Effect on Drug Levels** | **Effect on Zalcitabine Levels** | **Potential Clinical Effects** | **Mechanism of Interaction** | **Management** |
| Nevirapine[95](http://arv.ucsf.edu/insite?page=ar-00-02&param=22&post=4#95)  (NVP)(Viramune) | - | - | No significant change | Not studied | - | - | No dose adjustment necessary |
| Probenecid[287](http://arv.ucsf.edu/insite?page=ar-00-02&param=22&post=4#287),[85](http://arv.ucsf.edu/insite?page=ar-00-02&param=22&post=4#85)  (Benemid)(Benemid) | 500 mg at 8 hours and 2 hours before and 4 hours after zalcitabine | 1.5 mg x 1 dose | Not studied | Zalcitabine AUC: increased 54% | Increased zalcitabine effects | Inhibition of renal tubular secretion by probenecid | Dose adjustment not established |
| Saquinavir[85](http://arv.ucsf.edu/insite?page=ar-00-02&param=22&post=4#85)  (SQV)(Fortovase, Invirase) | - | - | No significant change | No significant change | - | - | No dose adjustment necessary |
| Zidovudine[85](http://arv.ucsf.edu/insite?page=ar-00-02&param=22&post=4#85)  (AZT, ZDV)(Retrovir) | - | - | No significant change | No significant change | - | - | No dose adjustment necessary |
| "-" indicates that there are no data available | | | | | | | |

|  |  |
| --- | --- |
| 85: | Hivid [package insert]. Nutley, NJ:Roche Laboratories Inc.;2001 |
| 95: | Viramune [package insert]. Ridgefield, CT: Boehringer Ingelheim Pharmaceuticals, Inc.; Nov 2005. |
| 232: | Aweeka FT, Brody SR, Jacobson M, et al. Is there a pharmacokinetic interaction between foscarnet and zalcitabine during concomitant administration? Clin Ther 1998;20:232-43. |
| 287: | Massarella JW, Nazareno LA, Passe S, et al. The effect of probenecid on the pharmacokinetics of zalcitabine in HIV-positive patients. Pharm Res 1996;13:449-52. |